Nuveen
ALXO icon

Nuveen’s ALX Oncology ALXO Stock Holding History

Nuveen’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Buy
+143,645
New +$257K ﹤0.01% 3505
2025
Q2 		– Sell
-164,790
Closed -$103K – 3279
2025
Q1 		$103K Hold
164,790
– – ﹤0.01% 3211
2024
Q4 		$275K Buy
164,790
+58,896
+56% +$90.5K ﹤0.01% 3144
2024
Q3 		$193K Hold
105,894
– – ﹤0.01% 3230
2024
Q2 		$639K Hold
105,894
– – ﹤0.01% 2911
2024
Q1 		$1.18M Hold
105,894
– – ﹤0.01% 2631
2023
Q4 		$1.58M Buy
105,894
+18,241
+21% +$173K ﹤0.01% 2516
2023
Q3 		$421K Sell
87,653
-10,411
-11% -$56.5K ﹤0.01% 2899
2023
Q2 		$736K Hold
98,064
– – ﹤0.01% 2792
2023
Q1 		$443K Sell
98,064
-7,001
-7% -$53K ﹤0.01% 2834
2022
Q4 		$1.18M Sell
105,065
-10,556
-9% -$119K ﹤0.01% 2622
2022
Q3 		$1.11M Sell
115,621
-1,198
-1% -$14K ﹤0.01% 2707
2022
Q2 		$945K Buy
116,819
+68,193
+140% +$743K ﹤0.01% 2806
2022
Q1 		$872K Sell
48,626
-15,230
-24% -$260K ﹤0.01% 2859
2021
Q4 		$1.37M Sell
63,856
-1,329
-2% -$57.3K ﹤0.01% 2736
2021
Q3 		$4.81M Sell
65,185
-29,752
-31% -$1.98M ﹤0.01% 2234
2021
Q2 		$5.19M Buy
94,937
+8,359
+10% +$500K ﹤0.01% 2226
2021
Q1 		$6.38M Buy
86,578
+39,673
+85% +$3.12M ﹤0.01% 2048
2020
Q4 		$4.04M Buy
46,905
+10,997
+31% +$662K ﹤0.01% 2178
2020
Q3 		$1.36M Buy
+35,908
New +$1.41M ﹤0.01% 2551

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Nuveen's ALXO Position: Q2 2026 in Review

Nuveen opened a new position in ALX Oncology (ALXO) in Q2 2026: 143,645 shares worth $297K. The stake represents ﹤0.01% of the portfolio and ranks #3505 among its holdings. This is a return to the name: Nuveen previously reported a position in ALXO as recently as Q1 2025.

Nuveen first reported a position in ALXO in Q3 2020 and has held it in 20 quarters since. The position peaked at $6.38M in Q1 2021. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Nuveen held 143,645 shares of ALX Oncology worth $297K as of Q2 2026.
  • ALX Oncology was a new Nuveen position in Q2 2026.
  • ALX Oncology made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3505 holding.
  • Nuveen first reported a position in ALX Oncology in Q3 2020 and has held it in 20 quarters since.
  • Nuveen's ALX Oncology position peaked at $6.38M in Q1 2021.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.